Webinar - Participant Realities and Engagement in Decentralized Clinical Trials

Today’s clinical trial landscape offers an unprecedented range of decentralized and hybrid options, including home health and community-based options. Digital solutions have been hailed as the path toward more inclusive trials yet many still struggle to recruit representative patient populations, despite clear regulatory guidance.  How can the feedback from participants in recent clinical trials help industry refine its DCT approach to be even more inclusive and responsive to patient preferences? How can industry work more collaboratively with advocates who possess distinct lines of site into their communities’ needs and experiences around trial participation?   

The Patient Choice Centered Research Initiative (PCCRI) asked recent clinical trial participants across a range of patient communities to reflect on their satisfaction with the operational aspects of their trial experience through a 50-question survey. PCCRI then collaborated with five patient advocacy groups with distinct patient population needs to analyze the findings alongside what they’ve heard from their own communities to turn insights into actionable, feasible DCT strategies that align to patient choice.  

This webinar will address how insights from this initiative and other patient-focused efforts can help to close geographic and digital health literacy gaps, decrease trial-related financial toxicities, and minimize burden for sites and patients.   

Our Speakers

Keri McDonough, Head, Patient Voice Consortium & Vice President, Medical and Scientific Strategy, Syneos Health 

Nicole Hemmenway, CEO, U.S. Pain Foundation 

Michelle Ouellette, Associate Director, Site & Patient Experience, Syneos Health  

Sarah Gillespie, Associate Director, Decentralized Clinical Trials, Syneos Health  

Learn More: 

Trend Talks: AgeTech with Musician, Actor & Patient Advocate, James Ian 

The Promise and Potential of Digital Mental Health Solutions 

Implementing Decentralized Clinical Trials: Strategic Design Vs. “Retrofitting”